Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis

Human Molecular Genetics

Volumn 23, Issue 16, 2014, Pages 4315-4327

  Flex, Elisabetta ^a   Jaiswal, Mamta ^b   Pantaleoni, Francesca ^a   Martinelli, Simone ^a   Strullu, Marion ^c,d   Fansa, Eyad K ^b   Caye, Aurélie ^c,d   De Luca, Alessandro ^e   Lepri, Francesca ^f   Dvorsky, Radovan ^b   Pannone, Luca ^a   Paolacci, Stefano ^a   Zhang, Si Cai ^b   Fodale, Valentina ^a   Bocchinfuso, Gianfranco ^g   Rossi, Cesare ^h   Burkitt Wright, Emma M M ⁱ   Farrotti, Andrea ^g   Stellacci, Emilia ^a   Cecchetti, Serena ^a   Ferese, Rosangela ^e   Bottero, Lisabianca ^a   Castro, Silvana ^j   Fenneteau, Odile ^c   Brethon, Benoît ^c   Sanchez, Massimo ^a   Roberts, Amy E ^k   Yntema, Helger G ^l   Van Der Burgt, Ineke ^l   Cianci, Paola ^m   Bondeson, Marie Louise ⁿ   Digilio, Maria Cristina ^f   Zampino, Giuseppe ^o   Kerr, Bronwyn ⁱ   Aoki, Yoko ^p   Loh, Mignon L ^q   Palleschi, Antonio ^g   Di Schiavi, Elia ^j   Caré, Alessandra ^a   Selicorni, Angelo ^m   Dallapiccola, Bruno ^f   Cirstea, Ion C ^b,r   Stella, Lorenzo ^g   Zenker, Martin ^s   Gelb, Bruce D ^t   Cavé, Héléne ^c,d   Ahmadian, Mohammad R ^b   Tartaglia, Marco ^a   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Department of Orthopedic Surgery   (Germany)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d INSERM   (France)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^k BOSTON CHILDREN S HOSPITAL   (United States)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m UNIVERSITY OF MILANO BICOCCA   (Italy)

ⁿ UPPSALA UNIVERSITY   (Sweden)

^o CATHOLIC UNIVERSITY   (Italy)

^p TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r FRITZ LIPMANN INSTITUTE   (Germany)

^s UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^t MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE DIPHOSPHATE; RAS PROTEIN; RRAS PROTEIN; UNCLASSIFIED DRUG; GLYCINE; GUANOSINE TRIPHOSPHATASE; LEUCINE; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE 12; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; VALINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; ONCOPROTEIN; RRAS PROTEIN, HUMAN;

ALLELE; ARTICLE; BINDING AFFINITY; CAENORHABDITIS ELEGANS; CELL ADHESION; CELL SPREADING; CLINICAL FEATURE; COMPUTER MODEL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FLUORESCENCE POLARIZATION; GENE ACTIVATION; GENE IDENTIFICATION; GENE INTERACTION; GERMLINE MUTATION; HUMAN; HUMAN CELL; HYDROPHILICITY; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMOGENESIS; MOLECULAR DYNAMICS; MORPHOGENESIS; NONHUMAN; NOONAN SYNDROME; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; SEGREGATION ANALYSIS; WILD TYPE; ACUTE GRANULOCYTIC LEUKEMIA; DEVELOPMENTAL DISORDER; RASOPATHY; SIGNAL TRANSDUCTION; SOMATIC MUTATION; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; CARCINOGENESIS; CHEMISTRY; COHORT ANALYSIS; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY;

CAENORHABDITIS ELEGANS;

ANIMALS; CAENORHABDITIS ELEGANS; CARCINOGENESIS; COHORT STUDIES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MAP KINASE KINASE KINASES; MUTATION; NOONAN SYNDROME; ONCOGENE PROTEIN V-AKT; PHENOTYPE; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84904763680     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu148     Document Type: Article

References (70)

1. Mitin, N., Rossman, K.L. and Der, C.J. (2005) Signaling interplay in Ras superfamily function. Curr. Biol., 15, R563-R574.
2. Mendoza, M.C., Er, E.E. and Blenis, J. (2011) The Ras-ERK and PI3K-mTORpathways: cross-talk and compensation. Trends Biochem. Sci., 36, 320-328.
3. Harris, T.J.R. and McCormick,F. (2010) The molecular pathology of cancer. Nat. Rev. Clin. Oncol., 7, 251-265.
4. Pylayeva-Gupta, Y., Grabocka, E. and Bar-Sagi, D. (2011) RAS oncogenes:weaving a tumorigenic web. Nat. Rev. Cancer, 11, 761-774.
5. Roberts, A.E., Allanson, J.E., Tartaglia, M. and Gelb, B.D. (2013) Noonan syndrome. Lancet, 381, 333-342.
6. Schubbert, S., Shannon, K. and Bollag, G. (2007) Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer, 7, 295-308.
7. Tartaglia, M. and Gelb, B.D. (2010) Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann. N. Y. Acad. Sci., 1214, 99-121.
8. Rauen, K.A. (2013) The RASopathies. Annu. Rev. Genomics Hum. Genet., 14, 355-369.
9. Aoki, Y., Niihori, T., Banjo, T., Okamoto, N., Mizuno, S., Kurosawa, K., Ogata, T., Takada, F., Yano, M., Ando, T. et al. (2013) Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am. J. Hum. Genet., 93, 173-180.
10. Tartaglia, M., Gelb, B.D. and Zenker, M. (2011) Noonan syndrome and clinically related disorders. Best Pract. Res. Clin. Endocrinol. Metab., 25, 161-179.
11. Kratz, C.P., Rapisuwon, S., Reed, H., Hasle, H. and Rosenberg, P.S. (2011) Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am. J. Med. Genet. C Semin. Med. Genet., 157C, 83-89.
12. Gripp,K.W.(2005)Tumorpredisposition in Costello syndrome. Am. J. Med. Genet. C Semin. Med. Genet., 137C, 72-77.
13. Loh, M.L. (2011) Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br. J. Haematol., 152, 677-687.
14. McKay, M.M. and Morrison, D.K. (2007) Integrating signals from RTKs to ERK/MAPK. Oncogene, 26, 3113-3121.
15. Dannenfelser, R., Clark, N.R. and Ma'ayan, A. (2012) Genes2FANs:connecting genes through functional association networks. BMC Bioinformatics, 13, 156.
16. Lowe, D.G., Capon, D.J., Delwart, E., Sakaguchi, A.Y., Naylor, S.L. and Goeddel, D.V. (1987) Structure of the human and murine R-ras genes, novel genes closely related to ras proto-oncogenes. Cell, 48, 137-146.
17. Wennerberg, K., Rossman, K.L. and Der, C.J. (2005) The Ras superfamily at a glance. J. Cell Sci., 118, 843-846.
18. Krengel, U., Schlichting, I., Scherer, A., Schumann, R., Frech, M., John, J., Kabsch, W., Pai, E.F. and Wittinghofer, A. (1990) Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell, 62, 539-548.
19. Saez, R., Chan, A.M., Miki, T. and Aaronson, S.A. (1994) Oncogenic activation of humanR-ras by point mutations analogous to those of prototype H-ras oncogenes. Oncogene, 9, 2977-2982.
20. Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., Filocamo, M., Kato, K., Suzuki, Y., Kure, S. et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat. Genet., 37, 1038-1040.
21. Bollag, G., Adler, F., elMasry, N., McCabe, P.C., Conner, E. Jr, Thompson, P., McCormick, F. and Shannon, K. (1996) Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. J. Biol. Chem., 271, 32491-32494.
22. Reimann, C., Arola, M., Bierings, M., Karow, A., van den Heuvel-Eibrink, M.M., Hasle, H., Niemeyer, C.M. and Kratz, C.P. (2006) A novel somatic K-Ras mutation in juvenile myelomonocytic leukemia. Leukaemia, 20, 1637-1638.
23. Murugan, A.K., Hong, N.T., Cuc, T.T., Hung, N.C., Munirajan, A.K., Ikeda, M.A. and Tsuchida, N. (2009) Detection of two novel mutations and relatively high incidence of H-RAS mutations in Vietnamese oral cancer. Oral. Oncol., 45, e161-e166.
24. Sartori, G., Cavazza, A., Sgambato, A., Marchioni, A., Barbieri, F., Longo, L., Bavieri, M., Murer, B., Meschiari, E., Tamberi, S. et al. (2009)EGFRand K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am. J. Clin. Pathol., 131, 478-489.
25. Milburn, M.V., Tong, L., deVos, A.M., Brünger, A., Yamaizumi, Z., Nishimura, S. and Kim, S.-H. (1990) Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science, 247, 939-945.
26. Diaz, J.F., Wroblowski, B., Schlitter, J. and Engelborghs, Y. (1997) Calculation of pathways for the conformational transition between the GTPand GDP-bound states of the Ha-ras-p21 protein: calculations with explicit solvent simulations and comparison with calculations in vacuum. Proteins, 28, 434-451.
27. Kuppens, S., Díaz, J.F. and Engelborghs, Y. (1999) Characterization of the hinges of the effector loop in the reaction pathway of the activation of ras-proteins. Kinetics of binding of beryllium trifluoride to V29G and I36G mutants of Ha-ras-p21. Prot. Sci., 8, 1860-1866.
28. Ma, J. and Karplus, M. (1997) Molecular switch in signal transduction:reaction paths of the conformational changes in ras p21. Proc. Natl. Acad. Sci. USA, 94, 11905-11910.
29. Gorfe, A.A., Grant, B.J. and McCammon, J.A. (2008) Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins. Structure, 16, 885-896.
30. Hall, B.E., Yang, S.S., Boriack-Sjodin, P.A., Kuriyan, J. and Bar-Sagi, D. (2001) Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange. J. Biol. Chem., 276, 27629-27637.
31. Suzuki, J., Kaziro, Y. and Koide, H. (1997) An activated mutant of R-Ras inhibits cell death caused by cytokine deprivation in BaF3 cells in the presence of IGF-I. Oncogene, 15, 1689-1697.
32. Scheffzek, K., Ahmadian, M.R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F. and Wittinghofer, A. (1997) The Ras-RasGAP complex:structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science, 277, 333-338.
33. Lundquist, E.A. (2006) Small GTPases. In WormBook. The C. elegans Research Community, WormBook (ed.), http://www.wormbook.org. doi:/10.1895/wormbook.1.67.1.
34. Sternberg, P.W. (2005) Vulval development. In Wormbook. The C. elegans Research Community (ed.), http://www.wormbook.org. doi:10.1895/wormbook.1.6.1.
35. Sundaram, M.V. (2006) RTK/Ras/MAPK signaling. In Wormbook. The C. elegans Research Community (ed.), http://www.wormbook.org. doi/10.1895/wormbook.1.80.1.
36. Eisenmann, D.M. and Kim, S.K. (2000) Protruding vulva mutants identify novel loci and Wnt signaling factors that function during Caenorhabditis elegans vulva development. Genetics, 156, 1097-1116.
37. Kishore, R.S. and Sundaram, M.V. (2002) ced-10 Rac and mig-2 function redundantly and act with unc-73 trio to control the orientation of vulval cell divisions and migrations in Caenorhabditis elegans. Dev. Biol., 241, 339-348.
38. Cordeddu, V., Di Schiavi, E., Pennacchio, L.A., Ma'ayan, A., Sarkozy, A., Fodale, V., Cecchetti, S., Cardinale, A., Martin, J., Schackwitz, W. et al. (2009) Mutation of SHOC2promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat. Genet., 41, 1022-1026.
39. Cox, A.D., Brtva, T.R., Lowe, D.G. and Der, C.J. (1994) R-Ras induces malignant, but not morphologic, transformation ofNIH3T3cells. Oncogene, 9, 3281-3288.
40. Wozniak, M.A., Kwong, L., Chodniewicz, D., Klemke, R.L. and Keely, P.J. (2005) R-Ras controls membrane protrusion and cell migration through the spatial regulation of Rac and Rho. Mol. Biol. Cell, 16, 84-96.
41. Osada, M., Tolkacheva, T., Li, W., Chan, T.O., Tsichlis, P.N., Saez, R., Kimmelman, A.C. and Chan, A.M. (1999) Differential roles of Akt, Rac, and Ral in R-Ras-mediated cellular transformation, adhesion, and survival. Mol. Cell. Biol., 19, 6333-6344.
42. Marte, B.M., Rodriguez-Viciana, P., Wennström, S., Warne, P.H. and Downward, J. (1997) R-Ras can activate the phosphoinositide 3-kinase but not theMAPkinase arm of the Ras effector pathways. Curr. Biol., 7, 63-70.
43. Jopling, C., van Geemen, D. and den Hertog, J. (2007) Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects. PLoS Genet., 3, e225.
44. Wang, S., Yu, W.M., Zhang, W., McCrae, K.R., Neel, B.G. and Qu, C.K. (2009) Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis. J. Biol. Chem., 284, 913-920.
45. Chen, P.C., Wakimoto, H., Conner, D., Araki, T., Yuan, T., Roberts, A., Seidman, C., Bronson, R., Neel, B., Seidman, J.G. et al. (2010) Activation of multiple signalling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J. Clin. Invest., 120, 4353-4365.
46. Emanuel, P.D. (2008) Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia, 22, 1335-1342.
47. Niemeyer, C.M. and Kratz, C.P. (2008) Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br. J. Haematol., 140, 610-624.
48. Matsuda, K., Shimada, A., Yoshida, N., Ogawa, A., Watanabe, A., Yajima, S., Iizuka, S., Koike, K., Yanai, F., Kawasaki, K. et al. (2007) Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood, 109, 5477-5480.
49. Flotho, C., Kratz, C.P., Bergsträsser, E., Hasle, H., Starý, J., Trebo, M., van den Heuvel-Eibrink, M.M.,Wójcik, D., Zecca, M., Locatelli, F. et al. (2008) Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood, 111, 966-967.
50. Takagi, M., Piao, J., Lin, L., Kawaguchi, H., Imai, C., Ogawa, A., Watanabe, A., Akiyama, K., Kobayashi, C., Mori, M. et al. (2013) Autoimmunity and persistent RAS-mutated clones long after the spontaneous regression of JMML. Leukaemia, 27, 1926-1928.
51. Park, H.D., Lee, S.H., Sung, K.W., Koo, H.H., Jung, N.G., Cho, B., Kim, H.K., Park, I.A., Lee, K.O., Ki, C.S. et al. (2012) Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia. Ann. Hematol., 91, 511-517.
52. Sakaguchi, H., Okuno, Y., Muramatsu, H., Yoshida, K., Shiraishi, Y., Takahashi, M., Kon, A., Sanada, M., Chiba, K., Tanaka, H. et al. (2013) Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat. Genet., 45, 937-941.
53. Van der Burgt, I., Berends, E., Lommen, E., van Beersum, S., Hamel, B. and Mariman, E. (1994) Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am. J. Med. Genet., 53, 187-191.
54. Allanson, J.E. (1987) Noonan syndrome. J. Med. Genet., 24, 9-13.
55. Sarkozy, A., Digilio, M.C. and Dallapiccola, B. (2008) LEOPARD syndrome. Orphanet J. Rare Dis., 3, 13.
56. Voron, D.A., Hatfield, H.H. and Kalkhoff, R.K. (1976) Multiple lentigines syndrome: case report and review of the literature.Am.J. Med., 60, 447-456.
57. Roberts, A., Allanson, J., Jadico, S.K., Kavamura, M.I., Noonan, J., Opitz, J.M., Young, T. and Neri, G. (2006) The cardiofaciocutaneous syndrome. J. Med. Genet., 43, 833-842.
58. Pérez, B., Kosmider, O., Cassinat, B., Renneville, A., Lachenaud, J., Kaltenbach, S., Bertrand, Y., Baruchel, A., Chomienne, C., Fontenay,M. et al. (2010) Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br. J. Haematol., 151, 460-468.
59. Guex, N. and Peitsch, M.C. (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis, 18, 2714-2723.
60. Martinelli, S., Torreri, P., Tinti, M., Stella, L., Bocchinfuso, G., Flex, E., Grottesi, A., Ceccarini, M., Palleschi, A., Cesareni, G. et al. (2008) Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum. Mol. Genet., 17, 2018-2029.
61. Bocchinfuso, G., Stella, L., Martinelli, S., Flex, E., Carta, C., Pantaleoni, F., Pispisa, B., Venanzi, M., Tartaglia, M. and Palleschi, A. (2007) Structural and functional effects of disease-causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP-2. Proteins, 66, 963-974.
62. Darden, T., York, D. and Pedersen, L. (1993) Particle mesh Ewald: an N. log(N) method for Ewald sums in large systems. J. Chem. Phys., 98, 10089-10092.
63. Berendsen, H.J.C., Postma, J.P.M., van Gunsteren, W.F., Di Nola, A. and Haak, J.R. (1984) Molecular dynamics with coupling to an external bath. J. Chem. Phys., 81, 3684-3690.
64. Gremer, L., Merbitz-Zahradnik, T., Dvorsky, R., Cirstea, I.C., Kratz, C.P., Zenker, M., Wittinghofer, A. and Ahmadian, M.R. (2011) Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum. Mutat., 32, 33-43.
65. Hemsath, L. and Ahmadian, M.R. (2005) Fluorescence approaches for monitoring interactions of Rho GTPases with nucleotides, regulators, and effectors. Methods, 37, 173-182.
66. Jaiswal, M., Dubey, B.N., Koessmeier, K.T., Gremer, L. and Ahmadian, M.R. (2012) Biochemical assays to characterise Rho GTPases. Methods Mol. Biol., 827, 37-58.
67. Eberth, A. and Ahmadian, M.R. (2009) In vitro GEF and GAP assays. Curr. Protoc. Cell Biol., 43, 14.9.1-14.9.25.
68. Cirstea, I.C., Gremer, L., Dvorsky, R., Zhang, S.C., Piekorz, R.P., Zenker, M. and Ahmadian, M.R. (2013) Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes. Hum. Mol. Genet., 22, 262-270.
69. Sulston, J.E. and Hodgkin, J. (1988) Methods. In Wood, W.B. and The Community of C. elegans Researchers (ed.), The Nematode Caenorhabditis Elegans. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,NY, pp. 587-606.
70. Mello, C.C., Kramer, J.M., Stinchcomb,D. and Ambros, V. (1991) Efficient gene transfer in C. elegans: extrachromosomal maintenance and integration of transforming sequences. EMBO J., 10, 3959-3970.